InMed Pharmaceuticals
9 hedge funds and large institutions have $206K invested in InMed Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
29% more funds holding
Funds holding: 7 → 9 (+2)
2.84% more ownership
Funds ownership: 8.1% → 10.94% (+2.8%)
14% less capital invested
Capital invested by funds: $241K → $206K (-$34.6K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$44.3K |
| 2 |
VF
Virtu Financial
New York
|
+$18.8K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$17.6K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$17.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$7.25K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$13.5K |
| 2 |
Jane Street
New York
|
-$12.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $142K | +$17.6K | +18,627 | +9% |
|
|
2
Citadel Advisors
Miami,
Florida
| $30.3K | +$44.3K | +46,973 | New |
|
|
VF
3
Virtu Financial
New York
| $13K | +$18.8K | +19,980 | New |
|
|
TSS
4
Two Sigma Securities
New York
| $12.1K | +$17.6K | +18,718 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $5.2K | +$7.25K | +7,691 | +2,040% |
|
|
PWMG
6
Private Wealth Management Group
Princeton,
New Jersey
| $3.23K | +$4.71K | +5,000 | New |
|
|
SS
7
SBI Securities
Tokyo,
Japan
| $193 | – | – | – |
|
|
FDCDDQ
8
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $2 | – | – | – |
|
|
9
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$13.5K | -12,753 | Closed |
|
|
10
Jane Street
New York
| – | -$12.7K | -11,978 | Closed |
|
INM Hedge Fund Activity: Q1 2026 in Review
9 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in InMed Pharmaceuticals (INM) for Q1 2026, worth a combined $206K — down 14% from $241K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new INM positions and 2 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $44.3K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $13.5K sold.
- 9 institutional investors held InMed Pharmaceuticals (INM) as of Q1 2026, up from 7 in Q4 2025.
- Funds reported $206K of InMed Pharmaceuticals stock for Q1 2026, down 14% quarter-over-quarter.
- 4 funds opened new InMed Pharmaceuticals positions in Q1 2026 and 2 closed out, a net change of +2 holders.
- The largest InMed Pharmaceuticals buyer in Q1 2026 was Citadel Advisors, an estimated $44.3K added.
- The largest InMed Pharmaceuticals seller in Q1 2026 was Susquehanna International Group, an estimated $13.5K sold.
Based on aggregated 13F filings for Q1 2026.